Complete Resolution of Locally Advanced Prostate Cancer After Molecular Endoradiotherapy With 177Lu-PSMA-Reference-Cited by-同舟云学术

Complete Resolution of Locally Advanced Prostate Cancer After Molecular Endoradiotherapy With 177Lu-PSMA

Published:2024-03-25 Issue:6 Volume:49 Page:e276-e277
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

Beheshti Mohsen¹,Vali Reza²,Zarehparvar Moghadam Soroush³,Amini HamidReza⁴,Hakiminejad Masoumeh⁵,Divband GhasemAli

Affiliation:

1. Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria

2. Division of Nuclear Medicine, Department of Diagnostic Imaging, The Hospital for Sick Children, Toronto, Ontario, Canada

3. Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad

4. Khatam PET/CT Center, Khatam-al-Anbia Hospital

5. Nuclear Medicine Center, Jam Hospital, Tehran, Iran.

Abstract

Abstract A 76-year-old man with castration-resistant prostate cancer underwent 68Ga–prostate-specific membrane antigen (PSMA) PET/CT for restaging. A large PSMA-avid tumor with invasion to adjacent organs was noted causing gross hematuria and symptomatic anemia. Two cycles of 177Lu-PSMA were administered, and the patient showed significant reduction of hematuria as well as declining in PSA levels. 177Lu-PSMA therapy can be a good treatment option in patients with locally invasive tumors.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference8 articles.

1. Synthesis and preclinical evaluation of 177Lu-labeled radiohybrid PSMA ligands for endoradiotherapy of prostate cancer;J Nucl Med,2022

2. 177Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: an updated systematic review and meta-analysis;Prostate,2022

3. Comparative preclinical biodistribution, dosimetry, and endoradiotherapy in metastatic castration-resistant prostate cancer using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T;J Nucl Med,2021

4. Clinical trial protocol for LuTectomy: a single-arm study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 prior to prostatectomy;Eur Urol Focus,2021

5. Excellent response to 177Lu-PSMA-617 radioligand therapy in a patient with advanced metastatic castration resistant prostate cancer evaluated by 68Ga-PSMA PET/CT;Clin Nucl Med,2017